Previous 10 | Next 10 |
home / stock / spgi / spgi articles
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 7.71% on an annualized basis producing an average annual return of...
-- New Energy Cloud Collaboration Facilitates Artificial Intelligence and Machine Learning Tools through S&P Global Data and Software -- NEW YO...
Organizations plan to link S&P Global Market Intelligence's Onboarding Accelerator with DTCC's ALERT with aim of delivering increased t...
The Nasdaq 100 closed lower by over 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares,...
S&P Global Inc (NYSE:SPGI) stock dropped after it reported its fourth-quarter results Thursday. The New York-based company clocked revenue gro...
U.S. stock futures suggest a subdued start for Wall Street on Thursday amidst anticipation of more earnings reports. The Dow may find support from&...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 8.34% on an annualized basis producing an average annual return of...
S&P Global (NYSE:SPGI) has outperformed the market over the past 5 years by 6.09% on an annualized basis producing an average annual return of ...
Goldman Sachs analyst George K. Tong expects companies in America's Business & Information Services sector to lean into technology and...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 10:15:02 ET BMO Capital analyst issues OUTPERFORM recommendation for SPGI on July 2, 2024 08:38AM ET. The previous analyst recommendation was Outperform. SPGI was trading at $446.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 PR Newswire NEW YORK , June 28, 202...
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...